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Destabilization of the tetrameric fold of TTR (transthyretin) is
important for aggregation of the protein which culminates in
amyloid fibril formation. Many TTR mutations interfere with
tetramer stability, increasing the amyloidogenic potential of
the protein. The vast majority of proposed TTR fibrillogenesis
inhibitors are based on in vitro assays with isolated protein,
limiting their future use in clinical assays. In the present study we
investigated TTR fibrillogenesis inhibitors using a cellular system
that produces TTR intermediates/aggregates in the medium.
Plasmids carrying wild-type TTR, V30M or L55P cDNA were
transfected into a rat Schwannoma cell line and TTR aggregates
were investigated in the medium using a dot-blot filter assay
followed by immunodetection. Results showed that, in 24 h, TTR
L55P forms aggregates in the medium, whereas, up to 72 h, wild-
type TTR and V30M do not. A series of 12 different compounds,
described in the literature as in vitro TTR fibrillogenesis
inhibitors, were tested for their ability to inhibit L55P aggregate
formation; in this system, 2-[(3,5-dichlorophenyl) amino] benzoic
acid, benzoxazole, 4-(3,5-difluorophenyl) benzoic acid and tri-
iodophenol were the most effective inhibitors, as compared with
the reference iododiflunisal, previously shown by ex vivo and
in vitro procedures to stabilize TTR and inhibit fibrillogenesis.
Among these drugs, 2-[(3,5-dichlorophenyl) amino] benzoic acid
and tri-iodophenol stabilized TTR from heterozygotic carriers of
V30M in the same ex vivo conditions as those used previously for
iododiflunisal. The novel cellular-based test herein proposed
for TTR fibrillogenesis inhibitor screens avoids not only lengthy
and cumbersome large-scale protein isolation steps but also
artefacts associated with most current in vitro first-line screening
methods, such as those associated with acidic conditions and the
absence of serum proteins.
Key words: aggregation, amyloid, anti-amyloidogenic drug,
iododiflunisal, transthyretin.
INTRODUCTION
FAP (familial amyloidotic polyneuropathy) is an autosomal
dominant disorder characterized by the extracellular deposition
of TTR (transthyretin) amyloid fibrils. This systemic disease has
particular deposition in peripheral nerve. Over 80 TTR mutations
have been related to amyloid deposition and disease [1], the most
frequent being a substitution of a methionine residue for valine at
position 30 (V30M). TTR is a homotetrameric protein produced
in the liver and in the choroid plexus of the brain and functions as
a transporter of T4 and vitamin A.
The knowledge acquired previously on structural and bio-
chemical features characteristic of amyloidogenic intermediates,
has paved the way for the investigation of drugs capable of
interfering early in the amyloidogenic pathway. For TTR-related
amyloidosis, the first step of a rational intervention is to obstruct
tetramer dissociation and thus prevent potential aggregation-prone
species from being generated. A second target is to inhibit the
association between conformational intermediate species that
lead to fibril elongation. Following these principles, several
authors have reported the identification of compounds capable
of inhibiting TTR fibril formation [2–6]. However, most of these
fibril inhibition studies were performed under non-physiological
acidic conditions believed to induce rapid conformational changes
and no specific distinction was made regarding the molecular
species affected by the drugs studied. Furthermore, these in vitro
tests were performed in the test tube using prokaryotic rather
than eukaryotic systems for the synthesis of human TTR. Cellular
systems represent a more physiological in vitro approach to study
inhibitors of amyloidogenesis which avoids isolation of the target
protein. In the present study we describe, for the first time, a
TTR-based cellular system for the screening of amyloid inhibitors.
Using this system we also report comparative results of the activity
of a series of drugs referred to in the literature as inhibitors of TTR
fibril formation.
MATERIALS AND METHODS
Vector constructions
Vectors p169ZT carrying human WT (wild-type) TTR (p169ZT-
hTTRwt) and p169ZT carrying human TTR L55P
(p169ZT-hTTR55) were generated as previously described [7].
We further produced a construct carrying the V30M TTR mutation
by site-directed mutagenesis using the QuikChange® mutagenesis
kit (Stratagene) following the manufacturer’s protocol and the
appropriate primers: 5′-AATGTGGCCATGCATGTGTTC-3′ and
5′-GAACACATGCATGGCCACATT-3′.
Transfection and TTR expression in cell culture
Rat Schwannomas (RN22) (American Type Cell Collection) were
stably co-transfected with each of the TTR cDNA constructs (WT,
V30M or L55P) plus a plasmid with resistance to neomycin
(pLNeo, provided by Dr Paulo Vieira, Pasteur Institute, Paris,
France) following the CaPO4–DNA precipitate method [8].
Briefly, cells were grown to approx. 30–50% confluence in
Abbreviations used: AA, amyloid A associated amyloidosis; DCPA, 2-(3,5-dichlorophenyl) amino benzoic acid; DES, diethylstilbestrol; DFPB, 4-(3,
5-difluorophenyl) benzoic acid; DNP, dinitrophenol; FAP, familial amyloidotic polyneuropathy; FCS, foetal calf serum; IEF, isoelectric focusing; PS2,
presenilin 2; TEM, transmission electron microscopy; TIP, tri-iodophenol; TTR, transthyretin; WT, wild-type.
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10 cm dishes (Costar). The appropriate purified cDNA TTR
plasmid (25 µg) plus 5 µg of purified pLNeo plasmid were
resuspended in 500 µl of 250 mM CaCl2 and diluted with 500 µl
2× Hepes-buffered saline (2X HEBS; 280 mM NaCl, 50 mM
Hepes, 1.5 mM Na2HPO4, pH 7.05). The CaPO4–DNA precipitate
was allowed to form by standing the mixture for 20 min at
room temperature (22 ◦C) and was subsequently added to the
cells. After 5 h incubation, cells were washed twice with PBS
and fed with 10 ml of DMEM (Dulbecco’s modified Eagle’s
medium; Gibco BRL) supplemented with 10% FCS (foetal calf
serum) and 1% penicillin/streptomycin (complete medium). At
24 h later, transfection medium (250 mM CaCl2 and 2XHEBS)
was replaced by complete medium supplemented with G418
(1 mg/ml). Resistant colonies arose after approx. 7 days of
selection and were isolated and separated over the course of the
following weeks.
TTR secretion was tested by quantitative ELISA [9]: 96-
well-plates (Maxisorp-Nunc) were coated overnight at 4 ◦C with
a polyclonal rabbit anti-human TTR antibody (1:500 dilution;
DAKO) and blocked with 5% (w/v) non-fat skimmed milk in
PBS; conditioned medium was applied to the wells for 1 h at room
temperature; a secondary peroxidase-conjugated anti-human TTR
antibody [The Binding Site; 1:500 dilution in PBS-T (PBS-
0.05% Tween 20)] was used. Development was performed with
ABTS [2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid;
Sigma]/H2O2. The TTR concentration in cell medium was
calculated from a standard curve ranging from 5 to 340 ng/ml.
Since the vector used is under the control of the metallothionein
promoter, experiments were performed in the presence of 100 µM
ZnSO4 in the cell culture medium in order to induce TTR
synthesis.
Immunoprecipitation and MS analysis
Zinc-treated cells expressing TTR were grown to approx. 100%
confluence in complete medium supplemented with G418 which
was then replaced by [14C]leucine-containing medium, and
collected 4 h later. Cells were harvested and then lysed with
1 ml of lysis solution [30 mM Tris/HCl (pH 7.5), 300 mM NaCl,
1% Triton X-100 and 10 µM PMSF], centrifuged for 30 min at
16000 g, the pellet was discarded and the supernatant collected.
Both medium and cell supernatant were incubated with a
rabbit anti-human TTR antibody (1:20 dilution; DAKO) and
kept overnight at 4 ◦C with stirring. Next, 150 µl of protein
A Sepharose beads [62.5 µg/µl in 30 mM Tris/HCl (pH 7.5)]
(CL-4B, Pharmacia) were added and allowed to mix for 1 h
at room temperature with agitation. The beads were washed
three times with washing solution [30 mM Tris/HCl (pH 7.5),
300 mM NaCl and 1% Triton X-100] and the complex was eluted
with SDS-loading buffer [62.5 mM Tris/HCl (pH 6.8), 2% SDS,
10% glycerol and 5% 2-mercaptoethanol]. Finally, samples were
fractioned on SDS/PAGE (15% gels) under denaturing conditions
and the gel was processed for autoradiography.
In some experiments, cells were grown in medium supple-
mented with 1% FCS and G418, for 24 h; the medium was col-
lected and processed for immunoprecipitation as described above.
After separation on an SDS/PAGE gel, proteins were stained
following a silver stain protocol. The TTR band was excized
from the gel and digested with trypsin. MALDI (matrix-assisted
laser-desorption ionization) MS analysis was performed on a
PerSeptive Voyager mass spectrometer in the linear mode [10].
Dot-blot filter assay for aggregate detection and drug assessment
Transfected and non-transfected cells were treated with ZnSO4
in complete medium supplemented with G418 for 3 days, grown
Table 1 Compounds tested for the inhibition of aggregate formation by TTR
L55P-expressing cells
Compound Reference
TIP [25]
Flufenamic acid [4]
Diflunisal [5]
Diclofenac [2]
Resveratrol [2]
DCPA [26]
DNP [27]
Benzoxazole [6]
Iododiflunisal [15]
DES [28]
Diclonisal [23]
DFPB [23]
Genistein [29]
to approx. 80% confluence and then incubated with serum-free
medium supplemented with ZnSO4 for different periods of time.
For the screening of drugs, cells were incubated with different
concentrations of each compound for 48 h, prior to the addition
of ZnSO4, and then for a further 3 days simultaneously with
ZnSO4. At that point, cells reached approx. 80% confluence
and were incubated with serum-free medium supplemented with
ZnSO4 and the desired drug for 24 h. TTR in the medium
was quantified by ELISA as described above, and 500 ng was
applied on to a 0.2 µm pore cellulose acetate membrane filter
(Schleicher and Schuell) using a manifold system (Gibco BRL)
under vacuum to separate soluble proteins from aggregates.
The filter was washed three times with PBS-T and processed
for TTR immunodetection. Briefly, the membrane was blocked
with 5% (w/v) non-fat skimmed milk in PBS for 1 h at room
temperature, and then incubated with a 1:500 dilution of a
rabbit anti-human TTR anti-serum (DAKO) for a further 1 h;
an anti-rabbit HRP (horseradish peroxidase) conjugate (1:500)
was used as the secondary antibody. Detection was performed
with ECL® (enhanced chemiluminescence; GE Healthcare). Dot-
blot quantification was performed using the ImageQuant program.
Experiments were repeated at least three times in duplicate and
the data shown are representative of the results obtained.
Chemical compounds studied for interaction with TTR
TIP (tri-iodophenol), flufenamic acid, diflunisal, diclofenac, res-
veratrol, DCPA {[2-(3,5-dichlorophenyl) amino] benzoic acid},
DNP (dinitrophenol), DES (diethylstilbestrol) and genistein were
from Sigma. The diflunisal derivative, iododiflunisal (Mr 376.1),
was synthesized as part of a screening programme for TTR
polymerization inhibitors carried out at IIQAB-CSIC, Barcelona,
and at the University of Oviedo, Oviedo, Spain. After synthesis,
the compounds were purified by HPLC (99.9% purity) and
characterized fully by NMR, MS and elemental analysis. The
synthetic procedure will be reported elsewhere; details are
available from G. Valencia on request. Benzoxazole, diclonisal
and DFPB [4-(3, 5-difluorophenyl) benzoic acid] were also
synthesized at IIQAB-CSIC and have been previously described
(Table 1). The compounds were weighed and dissolved at approx.
10 mg/ml in DMSO and used at a final concentration of 1 µM.
Recombinant protein
Recombinant TTR Y78F was produced in a bacterial expression
system using Escherichia coli BL21 [11] and purified as pre-
viously described [12]. The protein concentration was determined
using the Lowry method [13].
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Western blot analysis
In some experiments, after application of the medium on the
membrane filter, each dot was cut and boiled in SDS-loading
buffer. The removed material was run on a 15% SDS denaturing
acrylamide gel and then transferred on to a nitrocellulose
membrane (Amersham). The membrane was blocked with 5%
(w/v) non-fat skimmed milk in PBS for 1 h at room temperature
and then incubated with a 1:500 dilution of a rabbit anti-human
TTR anti-serum (DAKO) for a further 1 h at room temperature;
for the secondary antibody (1:5000 dilution) a peroxidase-
conjugated anti-rabbit IgG (Amersham) was used. Development
was performed with DAB (3′,3′-diaminobenzidine; Sigma).
TEM (transmission electron microscopy)
Inhibition of fibrillogenesis by selected drugs was evaluated using
TTR Y78F which aggregates under physiological conditions
(PBS, pH 7.4) after 2 days at 37 ◦C. For negative staining, 5 µl
of these preparations were adsorbed to glow-discharged carbon
collodion film on 200-square mesh copper grids for 1 min.
The grids were washed with deionized water and stained with
1% uranyl acetate (Fluka). Specimens were visualized with a
Zeiss electron microscope operating at 60 kV and grids were
exhaustively examined.
Assessment of tetrameric TTR stability by IEF (isoelectric focusing)
in semi-denaturing conditions
The conditions used for the IEF of plasma TTR have been
described previously by Altland et al. [14] and Almeida et al.
[15]. Briefly, 30 µl of plasma from a TTR V30M heterozygotic
carrier were incubated at 37 ◦C for 1 h, with 5 µl of a 10 mM
solution of the compound to be tested. The preparations were then
subjected to native PAGE to isolate TTR. The gel band containing
TTR was excised and subjected to IEF in a gel with 4 M urea and
5% ampholytes (pH 4–6.5) at 1200 V for 6 h. Proteins in the
gel were stained with Coomassie Blue. These semi-denaturing
conditions allow the visualization of bands corresponding to the
TTR monomer and tetramer and also to an oxidized form of
the monomer. Gels were scanned (HP Scanjet 4470c; Hewlett
Packard) and subjected to densitometry using the ImageQuant
program. Experiments were repeated at least three times and data
shown are representative of the results obtained.
Statistical analyses
All values are expressed as means +− S.E.M. Comparison between
groups was made using the Student’s t test. A P value of less than
0.05 was considered statistically significant.
RESULTS
TTR expression
To set up a cellular system for the production of TTR aggre-
gates, cells were transfected with different human TTR con-
structs (p169ZT-hTTRWT, p169ZT-hTTRV30M and p169ZT-
hTTRL55P). Demonstration of TTR secretion and quantification
of TTR levels in conditioned medium was performed by
quantitative ELISA after 24 h in serum-free conditions. Cells
were first treated with 100 µM ZnSO4 for 3 days to produce
TTR. The medium was then replaced by serum-free medium
for 24 h and TTR in the medium was quantified by ELISA
as detailed in the Materials and methods section. The interval
ranges of TTR expression differed; for TTR WT this varied from
100–300, was 350–1000 for TTR V30M and 300–900 for TTR
L55P (expressed in ng/ml/106cells/24 h).
Protein expression and degradation was also assessed by im-
munoprecipitation on both medium and cell lysates. Figure 1(A)
shows TTR from medium and cell lysates (pellet), separated under
denaturing conditions (SDS/PAGE) after immunoprecipitation
with an anti-human TTR antibody, and revealed that most of the
protein produced was secreted into the medium as soluble non-
degraded material. To further confirm the identity of each TTR
variant expressed and secreted by the cells, we performed MS
analysis of the protein in the conditioned medium of transfected
cells. The results are displayed in Figure 1(B) which highlights the
particular peaks corresponding to each mutation, thus confirming
the expected TTR variant in each transfection. As shown in the
left-hand panel of Figure 1(B2), a peptide of Mr 2181, representing
residues 16–35 of TTR but with a methionine residue replacing
valine, was detected in the preparation derived from TTR V30M
transfected cells, not present in the preparation of the right-hand
panel (derived from TTR L55P transfected cells), which had the
corresponding non-mutated, normal Mr 2149 peptide. Conversely,
in the preparation derived from TTR L55P transfected cells (right-
hand panel), a mutated peptide of Mr 3126, representing residues
49–76 of TTR but with a proline residue replacing leucine, was
detected, which was absent from the V30M preparation; instead,
a normal, non-mutated peptide of Mr 3142 was observed.
Production of amyloidogenic TTR species
We next investigated the ability of the different constructs to
induce the production of amyloidogenic species. Cells were grown
in serum-free medium for 24, 48 or 72 h and then the medium
was analysed for the presence of aggregated material retained by
a 0.2 µm filter in a dot-blot assay. Although TTR aggregates were
not detected in medium from cells transfected with constructs
carrying the TTR WT or TTR V30M cDNA even after 72 h of
cell culture, TTR L55P protein material was partially retained
by the membrane filter as early as 24 h into culture (Figure 2A),
suggesting the formation of oligomers or aggregates.
The dotted area was analysed by SDS/PAGE. The proteins were
then transferred on to a nitrocellulose membrane and followed by
immunodetection against TTR (Figure 2B), revealing the intact
TTR monomer; under these conditions we did not have evidence
for aggregate formation since SDS disrupted those aggregates.
Even under denaturing conditions, TTR did not completely dis-
sociate into monomers, originating a second band corresponding
to the dimer with an apparent mass of approx. 32 kDa.
Comparative effects of diflunisal and iododiflunisal on TTR L55P
aggregation
We next evaluated this system in the screening of drugs capable
of interfering with TTR fibrillogenesis. Previously, it has been
reported that an iodinated diflunisal derivative, iododiflunisal, was
very potent as a TTR fibrillogenesis inhibitor, and as a stabilizer
of the TTR tetrameric fold when compared with diflunisal [15],
as assessed by in vitro and ex vivo approaches respectively. In the
present study, we started by studying in our cellular system the
effect of different iododiflunisal concentrations (0.01–10 µM)
on TTR aggregation. As depicted in Figure 3(A), iododiflunisal
inhibited L55P aggregate formation at concentrations between
0.1–10 µM.
We next compared the inhibitory activity on TTR L55P
fibrillogenesis of diflunisal and iododiflunisal at three different
concentrations: 0.1, 1 and 10 µM. Results are shown in
Figure 3(B) and show that iododiflunisal was able to inhibit
aggregate formation at 0.1 µM, whereas for diflunisal, the same
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Figure 1 TTR expression in transfected cells
(A) Immunoprecipitation analysis of RN22 cell medium and pellet from non-transfected cells (NT) and from cells transfected with plasmids for TTR WT, V30M and L55P. (B) MS analysis of
immunoprecipitated TTR from conditioned medium of TTR V30M and L55P transfected cells. After immunoprecipitation, proteins were separated on a SDS/PAGE gel which was silver stained (B1).
MW, molecular mass standards; TTR std, standard TTR; NT, non-transfected cells. The bands corresponding to the TTR protein (indicated with an arrow) were cut, digested with trypsin and analysed
by MS (B2), revealing specific peptides for TTR V30M (left-hand panel) and for L55P (right-hand panel).
Figure 2 Aggregation in conditioned medium of RN22 cells
(A) Dot-blot filter assays of medium from non-transfected RN22 cells or cells transfected with
plasmid for WT and TTR mutants (V30M and L55P). TTR was quantified in the medium by
ELISA and 500 ng was applied in the filter, followed by TTR immunodetection. (B) Western blot
analysis of the material retained on the membrane filter revealed the presence of TTR (lane 1).
Lane 2 shows the TTR standard. In both lanes the TTR monomer and dimer are observed. MW,
molecular mass standard.
effect was only observed at a concentration of 10 µM. Thus
iododiflunisal presented a 100-fold increase in inhibitory activity
when compared with diflunisal. These observations confirmed
the data referred to above indicating the much higher capacity of
iododiflunisal over diflunisal to prevent TTR fibrillogenesis.
It is noteworthy that some variation occurred in these assays.
However, the relative intra-assay activities between different
drugs and between drugs and control remained significant,
despite inter-assay fluctuations. For example, 0.1 µM of iododi-
flunisal inhibited L55P fibril formation by 25% as displayed
in Figure 3(A), but by 90% as shown in Figure 3(B). Despite
this variation, statistical significance was observed with the
iododiflunisal in both experiments, when compared with the res-
pective control.
Comparative aggregate inhibitory activities of selected compounds
Following the results described above and to further assess the
usefulness of the cellular model for screening purposes, we
continued our studies on this cellular system with different drugs.
We evaluated a series of compounds, selected based on their
ability to inhibit amyloid fibril formation according to previously
published literature (for references see Table 1), which in most
cases used isolated recombinant TTR upon acidification to pH 4.4
and monitoring of turbidity at 400 nm. A further criterion for
lead compound selection was individual products representative
of different therapeutic categories such as, for instance, NSAIDs
(non-steroidal anti-inflammatory drugs: diflunisal, diclofenac and
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Figure 3 Comparative effects of diflunisal and iododiflunisal on TTR L55P
aggregation
(A) Effect of different concentrations of iododiflunisal in L55P aggregate formation. Conditioned
medium containing 500 ng of total TTR of cells expressing TTR L55P treated with different
concentrations of iododiflunisal (0.01, 0.02, 0.1, 0.5, 1, 5 and 10 µM) or non-treated was applied
on to an acetate cellulose membrane filter, followed by immunodetection of TTR aggregates
with a specific anti-human TTR antibody, and quantified using the ImageQuant program.
*P < 0.02. (B) Dot blot showing the effect of three different concentrations of iododiflunisal and
diflunisal in L55P aggregate formation. The experiment was performed as in (A) and revealed that
iododiflunisal has approx. 100-fold greater ability of preventing L55P aggregate formation than
diflunisal. The histogram shows densitometric analysis of the dot blot showing the percentage of
inhibition of aggregate formation by each compound, compared with the control (0 % inhibition,
no drug added). *P < 0.03. I-Dif, iododiflunisal.
flufenamic acid) or compounds sharing molecular structural
similarities with those (DCPA, DFPB and diclonisal). Other
small organic compounds also referred to as good amyloid
inhibitors such as plant compounds (genistein and resveratrol),
DES, benzoxazole and TIP were also selected for testing. Thus the
compounds listed in Table 1 were tested at a 1 µM concentration
and the results are shown in Figure 4. Different levels of inhibition
were evident when compared with the iododiflunisal control
(Figure 4, histogram). Among the compounds tested, TIP showed
an inhibitory capacity similar to that of iododiflunisal (approx.
57% inhibition). Three of the compounds analysed revealed
to be more efficient than iododiflunisal (DCPA, DFPB and
benzoxazole), inhibiting aggregate formation in more than 80%.
For the other assessed compounds including DES, resveratrol,
diflunisal, DNP, genistein, diclofenac, diclonisal and flufenamic
acid, no inhibitory effect was evident when compared with the
control. Conditioned medium incubated with compounds just
prior application on to the membrane showed a signal equivalent
to conditioned medium alone (results not shown), ruling out a
possible effect of the compounds on the immunoassay.
Figure 4 Screening for TTR anti-amyloidogenic drugs
Filter assays of the conditioned medium from TTR L55P cells incubated with different drugs at
a concentration of 1 µM. Conditioned medium of cells incubated with iododiflunisal and TIP,
showed significantly less aggregates than control. DCPA, DFPB and benzoxazole showed the
highest inhibitory effect whereas all of the other eight compounds tested produced no effect.
The histogram shows densitometric analysis of the dot blot showing the percentage of inhibition
of aggregate formation by each compound compared with the control (0 % inhibition, no drug
added). *P < 0.006. Benzo, benzoxazole; Diclof, diclofenac; Diclon, diclonisal; Dif, diflunisal;
Fluf, flufenamic acid; I-Dif, iododiflunisal; Resv, resveratrol.
TEM
To compare the results obtained in the cellular model, we analysed
the effect of six of the drugs under study (genistein, TIP, DES,
DCPA, DFPB and benzoxazole ) by TEM. This was performed
with a different TTR variant, TTR Y78F, which is very prone to
aggregation as compared with the L55P mutant. The soluble Y78F
variant aggregates in about 48 h at pH 7.4, as reported by Almeida
et al. [15] who observed that upon incubation with iododiflunisal
no aggregates were visible and only round particles resembling the
native TTR were present; in contrast, incubation with diflunisal
or diclofenac did not prevent aggregate formation [15].
Figure 5 is representative of the results obtained in the
present study and shows a complete inhibition of aggregate and
fibril formation with DFPB and benzoxazole (bottom panels);
DCPA was only able to partially inhibit aggregate and fibril
formation (top right-hand panel). TIP inhibited aggregate and
fibril formation whereas the addition of genistein and DES
resulted in no visible effect by TEM (results not shown).
In vitro and ex vivo activities of selected compounds
The same panel of compounds was further tested ex vivo for their
effect on TTR stability by IEF analysis under semi-denaturing
conditions, namely in the presence of 4 M urea. To perform
the assays we basically used the same conditions as in previous
studies [15]. Plasma from a heterozygotic carrier of TTR V30M
was incubated with each of the compounds referred to in the
legend of Figure 6 and, following IEF, the bands corresponding
to the TTR tetramer and monomer were visualized, and the
tetramer/monomer ratio was measured. Under the conditions
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Figure 5 Morphological analysis of TTR Y78F by TEM
TTR Y78F incubated for 48 h at 37◦C evolved from round particles to fibrils (control; top
left-hand panel). When incubated with DFPB or benzoxazole, fibril formation was completely
inhibited (bottom panels) whereas incubation with DCPA produced only a partial inhibition (top
right-hand panel).
Figure 6 Stabilization of tetrameric TTR V30M
Plasma from a heterozygotic carrier of TTR V30M was incubated with different drugs. TTR was
then separated by PAGE and the isolated protein was analysed by IEF. The different molecular
species visualized in the IEF gel after Coomassie Blue staining are indicated. In the presence of
iododiflunisal, DCPA and TIP, stronger bands corresponding to TTR tetramers were visualized
and the monomer bands were strongly reduced or absent. The histogram shows densitometric
analysis of IEF of isolated TTR V30M incubated with the different compounds and expressed
as the tetramer/monomer ratio. *P < 0.006. Benzo, benzoxazole; Diclof, diclofenac; Diclon,
diclonisal; Dif, diflunesal; Fluf, flufenamic acid; I-Dif, iododiflunisal; Resv, resveratrol.
used, TTR presented a characteristic pattern of two main bands,
representing monomers (normal and oxidized form), and several
bands of lower pI, representing different forms of tetramers.
As compared with iododiflunisal, a similar stabilization effect
was obtained with DCPA and with TIP, not evident for
DFPB and benzoxazole under the conditions used. All of the
other compounds in the cellular assay without inhibitory TTR
fibrillogenesis activity failed to stabilize V30M ex vivo.
DISCUSSION
The process that converts a soluble protein into amyloid is
complex and not fully understood. TTR amyloid deposits have
been suggested as the causative agent of FAP. However, the
finding that asymptomatic individuals carrying the TTR V30M
mutation show a positive reaction for inflammatory markers
and present non-fibrillar TTR deposits in the nerve raised the
possibility that species besides mature fibrils could be involved in
the disease [16]. In fact, in vitro studies have shown that TTR L55P
aggregates are toxic to a Schwannoma cell line, inducing caspase 3
activation, whereas long fibrils do not produce significant caspase
3 activation. These observations suggest that a major target in
FAP therapy is to inhibit the formation of intermediate species
and that understanding of how native TTR converts into a toxic
species is of major importance.
Initially most in vitro studies on TTR amyloidogenesis
were performed by acidifying the protein [2,3,5,6], using an
environment different from in vivo conditions. More recently,
TTR variants such as Y78F, which are able to produce aggregates
and fibrils at physiological pH have benefited research on anti-
amyloidogenic drugs and disease mechanisms by avoiding pH-
related artefacts. In both cases (with and without acidification),
most studies are still conducted with purified recombinant
proteins [2–6] and thus such approaches lack factors that occur
in vivo. Thus a cellular system producing the amyloidogenic
protein would represent an improved approach to study effects
of modulating factors and drugs on fibrillogenesis. In fact,
different cellular models have been generated in order to study
amyloidogenesis. A cell culture system for generation of AA
(amyloid A associated amyloidosis) was established using murine
peritoneal macrophages after repeated injections of Hammersten
casein [17]. Staining with Congo Red, thioflavin T and anti-
AA revealed amyloid-like structures associated with macrophage
clusters. Such systems can be useful in studies on the influence
of chaperone molecules and other factors on the formation and
degradation of amyloid fibrils. Similarly, cells transfected with the
PS2 (presenilin 2) gene were used to examine the processing and
degradation pathways of PS2 [18]. Furthermore, different cellular
models have been created in order to study many different aspects
of Alzheimer’s disease [19–21]. In the present study we report
on the establishment of a cellular system of transfected RN22
(rat Schwannoma) with WT TTR, V30M and L55P mutants. The
latter was shown to form species that were retained by a filter, in
contrast with the WT and V30M proteins.
Although being the most prevalent mutation responsible for
the pathology, V30M does not show a very high amyloidogenic
potential in vitro, since amyloid fibrils are only obtained after
acidification. Furthermore, X-ray crystallography studies [22]
revealed a structure similar to the WT counterpart and the
differences found could not explain a significant instability of
the protein. Thus, in vivo, this mutation plays a very important
role in the pathology of FAP but, in vitro, the protein does not
lend itself to study by the assays described in the present paper.
One of the advantages of this in vitro cellular system is that
it measures aggregation under good physiological conditions
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because: (i) it uses a eukaryotic system for the production of
TTR; (ii) the secreted protein is not isolated, avoiding modifi-
cations such as oxidations that might influence aggregation; and
(iii) aggregation occurs in the cell medium, under physiological
pH and in the presence of serum proteins. None of the previous
in vitro available methodologies to screen for TTR inhibitors take
into consideration these aspects, as TTR aggregation is measured
on isolated recombinant TTR from bacteria and in the absence of
serum proteins.
When the 12 compounds classified in the literature as
good TTR fibrillogenesis inhibitors were tested on the cellular
system, having iododiflunisal as the reference compound, only
DCPA, benzoxazole, DFPB and TIP were able to prevent L55P
aggregate formation in the conditioned medium, which reflects
the above-mentioned limiting conditions, such as the aggressive
environment imposed by acidification, the exclusive use in most
instances of WT rather than mutant TTR and the absence of serum
proteins [4,23,24]. With regard to the ultrastructural analysis,
DCPA did not show an inhibitory effect as high as DFPB and
benzoxazole, indicating that the Y78F mutant may not be as
sensitive to this drug as TTR L55P and V30M are. Stabilization of
tetrameric V30M TTR by iododiflunisal was previously shown in
ex vivo tests using plasma from hetero- and homo-zygous carriers.
The sample was directly analysed without previous treatment
with cross-linkers and did not suffer further processing such
as immunoprecipitation. Urea (4 M) allowed discrimination of
susceptibility to tetramer dissociation into monomeric species,
directly visualized on the IEF gel without the use of TTR
antibodies for quantification of the tetramer/monomer ratio. We
also did not observe a stabilizing effect of benzoxazole and DFPB
by ex vivo testing under the conditions used; this fact is suggestive
that these two drugs either inhibit TTR fibrillogenesis by
mechanisms other than tetramer stabilization, such as inhibition
of polymerization of soluble intermediary species generated after
tetramer dissociation, or alternatively they might have a more
effective anti-fibrillogenic effect in L55P and in Y78F.
At any rate, testing of the V30M variant is most pertinent in
studies searching for TTR anti-fibrillogenic drugs as besides being
the most common mutant found in FAP, further application of the
drug under study encompasses in vivo testing in animal models
which are available for this mutant [7].
The main conclusions of this screening work indicate that: (i)
iododiflunisal, DCPA and TIP are the best stabilizers of V30M
tetramers in plasma from carriers of this mutant, and clearly inhibit
aggregation in the cellular system; also, DFPB displayed anti-
aggregation properties for L55P and Y78F but did not stabilize
V30M tetramers, possibly by acting through mechanisms other
than tetrameric stabilization. Therefore iododiflunisal, DCPA and
TIP are promising for the treatment of V30M-associated FAP but
need to undergo further stages of drug development to overcome
their toxicity. (ii) Compounds with virtually null stabilization of
the tetrameric structure (as assessed ex vivo), such as flufenamic
acid, diclofenac, resveratrol, genistein, diflunisal and DES, clearly
had no effect on TTR aggregation in cell culture and thus further
testing of them may not be worthwhile.
The cellular model described in the present study represents
a step forward in the study of events occurring very early
in TTR amyloidogenesis and of factors/drugs affecting such
processes; moreover, our cellular model supplies a unique tool
to test drugs independently of the mechanism behind their action,
i.e. tetramer stabilization, inhibition of aggregation and others.
We believe that this system will have important implications in
future drug screening and design while constituting an important
tool for the selection of compounds that merit preclinical
testing.
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